MENU

Fox Chase Cancer Center News

There may be important genetic differences among different black ethnic subgroups relevant to cancer.
August 23, 2019

Knowledge of Black Ethnic Subgroups Could Aid in Addressing Cancer Disparities

PHILADELPHIA (August 23, 2019) – New data from researchers at Fox Chase Cancer Center shows there may be important genetic differences among different black ethnic subgroups relevant to cancer.

In Pennsylvania, the incidence and mortality rates of liver cancer have climbed each year since 2003.
August 23, 2019

Fox Chase Faculty Members Receive Pennsylvania Department of Human Services Grant for Liver Cancer Education

PHILADELPHIA (August 23, 2019) — Evelyn González and Shannon Lynch, MPH, PhD, have received a two-year grant for $125,000 from The Pennsylvania Department of Human Services to provide liver cancer and hepatitis education to at-risk communities in the Philadelphia area. Up to 70 percent of liver cancer cases are caused by modifiable factors, including drug or alcohol use, obesity, diabetes, and infection with hepatitis B or C.

Dr. Greco, MD, who will join the Department of Surgical Oncology as an assistant professor on the academic clinician track. She will focus on melanoma, sarcoma, and GI.
August 21, 2019

Fox Chase Cancer Center Welcomes Stephanie Greco

PHILADELPHIA (August 21, 2019) – Fox Chase Cancer Center announces the hiring of Stephanie Greco, MD, who will join the Department of Surgical Oncology on September 3, focusing on melanoma, sarcoma, and GI.

August 20, 2019

Elotuzumab Promotes Unique SLAMF7-SLAMF7 Interactions That Enhance Cytotoxicity in Myeloma

PHILADELPHIA (August 20, 2019) – The immunostimulatory monoclonal antibody elotuzumab, given in combination with lenalidomide and dexamethasone, is approved for the treatment of patients with relapsed or refractory multiple myeloma. The drug binds signaling lymphocytic activation molecule family member 7 (SLAMF7), a protein that is highly expressed on the surface of myeloma cells.

August 19, 2019

Fox Chase Cancer Center Proudly Participates in the Undy RunWalk 2019

PHILADELPHIA (August 19, 2019) – Fox Chase Cancer Center will proudly participate in the Philadelphia Undy RunWalk to support the Colorectal Cancer Alliance and their mission to end colorectal cancer with national prevention, research, and patient support initiatives. Saturday, September 14, 2019, in Paine’s Park.

Disruption of HSP90 function can lead to death of ovarian cancer cell lines without known defects in DNA repair mechanisms, such as BRCA1/2 mutations, when used in combination with a PARP inhibitor.
August 16, 2019

PARP Inhibitors Could Repair DNA in Ovarian Carcinoma Cancer Cells

PHILADELPHIA (August 16, 2019) – Recently, Fox Chase Cancer Center researchers found a potential way to sensitize a new subset of patients with high-grade serous ovarian carcinoma to PARP inhibitors, a promising drug used in some cases of this disease. Disruption of HSP90 function can lead to death of ovarian cancer cell lines without known defects in DNA repair mechanisms, such as BRCA1/2 mutations, when used in combination with a PARP inhibitor.

August 16, 2019

Fox Chase Researchers Characterize Structure of Receptor That Helps Mediate Activity of Natural Killer Immune Cells

PHILADELPHIA (August 16, 2019) – Natural killer cells, which have an innate capacity to identify and kill tumor cells or virus-infected cells in humans, are an important part of the body’s immune system. Key in distinguishing healthy cells from abnormal cells by natural killer cells is their expression of killer cell immunoglobulin-like receptors (KIRs).

August 16, 2019

In-Depth Look at RAS Mutations Highlight Age-Related Molecular Differences in CRC

PHILADELPHIA (August 19, 2019) – A new study by researchers at Fox Chase Cancer Center provides more evidence that colorectal cancers diagnosed in younger patients may be distinct from those diagnosed in older patients.

Pages

Connect with Fox Chase